Hepatitis C

Positive results reported on interferon-alpha variants

Published in Vaccine Weekly, October 23rd, 2002

GenOdyssee S.A., a biotherapeutics company specializing in discovering and developing drugs from functional genomics, announced preclinical results for its proprietary interferon (IFN) alpha variants for the treatment of hepatitis C (HCV) and cancer.

In the studies conducted by independent French laboratories, GenOdyssee's variants demonstrated up to 1 hundred times greater efficacy compared with IFN alpha molecules currently on the market.

Michael Tovey, director of the Viral Oncology Laboratory at CNRS Research Institute (French National Center for Scientific Research) commented, "GenOdyssee's interferons display excellent toxicity profiles and are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry